FDA Updates Warning Labels On Blockbuster Drugs
The U.S. Food and Drug Administration announced the findings of its first post-marketing review of of Novartis AG's Exjade, used to treat chronic iron overload in patients receiving regular blood transfusions,...To view the full article, register now.
Already a subscriber? Click here to view full article